Satellite Symposia
The Satellite Symposia are industry-sponsored, programs offered in conjunction with ASH specialty meetings. These events are offered in conjunction with the 2024 Highlights of ASH in the Mediterranean and are not part of the official ASH meeting programming and are planned solely by the sponsoring company. There is no fee to attend and registration to HOA is not required to participate.
The 2024 Satellite Symposia are each presented in-person, once, live at the date, time, and location listed. For program-specific questions, please reach out to the managing company contact listed below each session.
Lilly
The role of Jaypirca as covalent BTKi in Relapse/Refractory MCL
March 1, 2024, 10:30 a.m. To 11:00 a.m.
Join our expert Prof Von Kresckow from Germany as he discusses the unmet need in patients with relapse refractory MCL and discusses the latest innovative cobalent BTKi Jaypirca and how it supports in restabilising BTK pathway. The audience will have an opportunity to ask questions at the end of the session.
Speaker: Prof Bastian von Tresckow
Deputy Director
Department of Hematology and Stem Cell Transplantation
Professor (W2) of Clinical and Experimental Hematology
Lead of University Hospital Essen CAR-T and lymphoma program
West German Cancer Center Essen
University Hospital Essen
Bastian von Tresckow is Deputy Director at the Department of Hematology and Stem Cell Transplantation, University Hospital Essen and Lead of the University Hospital Essen adult CAR-T and lymphoma program.
In 2001 he joined Professor Andreas Engert's laboratory in Cologne as a medical student and started to perform basic research in Hodgkin Lymphoma. Since 2005 he has worked as a clinical physician with a focus on hematologic malignancies. He joined the German Hodgkin Study Group (GHSG) in 2005. Between 2005 and 2007 he received a grant from the “Köln Fortune”-programme and performed scientific work in Professor Andreas Engert’s group: Investigation of small molecules for the treatment of Hodgkin Lymphoma. Dr von Tresckow
received board certification in 2011 as a specialist in internal medicine and haematology and oncology. In 2012 he joined Cochrane Haematology as an editor. Since 2020, his present position is Deputy Director at the Department of Hematology and Stem Cell Transplantation, University Hospital Essen. Within the GHSG, he is responsible for relapsed/refractory disease. The research foci of Bastian von Tresckow are clinical trials in lymphoma (focus on relapsed lymphoma), minimal residual disease (MRD) and response assessment in lymphoma, chimeric antigen receptor (CAR)-T cell therapy and evidence-based medicine
Bristol Myers Squibb
Reblozyl in real-life practice
March 1, 2024, 11:00 a.m. To 11:30 a.m.
Luspatercept a first in class Erythroid maturation agent has been approved in 2021 within the UAE. In this session the audience will get the opportunity to learn about real life clinical experience vs clinical trial outcomes, bridging the gap between trial outcomes and treatment expectations in real life setting.
Speaker: Dr. Amar Lal
Amar Lal, MBBS MCPS FCPS (Medicine) FCPS (Oncology) MRCP (Ireland) MRCPS (Glasgow)
MRCP-SCE (Oncology) ESMO-Board
Consultant, Oncology Department, Tawam Hospital
Novo Nordisk
Addressing the unmet needs in Hemophilia: Advances in Treatment and Future Directions
March 1, 2024, 11:30 a.m. To 12:00 a.m.
In an evolving haemophilia landscape, therapeutic advancements are being made across all haemophilia subtypes, addressing unmet needs, especially in haemophilia.
In this lecture we will discuss:
- Current unmet needs in treatment and management of hemophilia A.
- Role of Extended half-life Factor VIII products in reducing the burden of treatment.
- Positive impact of EHLs on Quality of life of patients with hemophilia.
Speaker: Dr. Mehran Karimi is professor emeritus of pediatric hematology and oncology.
He has been practicing in the field of hemophilia, rare bleeding disorders, hemoglobin disorders, pediatric solid tumors, and leukemia/lymphoma for a period of 26 years. Dr. Karimi has been working in Dubai as a pediatric hematologist-oncologist since 2012. He is a member of national and international scientific societies. He authored more than 390 articles and more than 350 abstracts in peer-reviewed journals and has been invited as a speaker at many national and international conferences.
SANDOZ
Biosimilars as the Value-Based Biologics in Oncology
March 1, 2024, 12:00 p.m. To 12:30 p.m.
Join our experts Dr. Shaheenah Dawood and Dr. Amar Lal as they discuss the role of biosimilars in the oncology and hematology fields. Our experts, chaired by Dr. Mahmoud Marashi, will review clinical trials and real-world data across the globe for Rixathon and Zarzio, as well as share their own clinical experience. The audience will have an opportunity to ask questions at the end of the session.
Speaker: Dr. Mahmoud Marashi (Chair), Dr. Shaheenah Dawood and Dr. Amar Lal
Roche
Columvi Bi specifics: New era for treating heavily pre-treated DLBCL patients
March 1, 2024, 12:30 p.m. To 01:00 p.m.
In an evolving DLBCL landscape, therapeutic advancements are being made across all DLBCL subtypes, addressing unmet needs, especially in relapsed/refractory setting with heavily pretreated patients. This expert-led symposium will discuss:
- The potential value of Bi specifics as a new approach in treating DLBCL.
- Bi specifics as an emerging class of treatment
- The efficacy, safety, and convenience of Columvi in treating heavily pretreated DLBCL subtypes.
Speaker: Dr. Amar Lal
Consultant, Oncology Department, Tawam Hospital
Stemline
How to manage and treat patients with BPDCN
March 1, 2024, 02:00 p.m. To 02:20 p.m.
Join our expert, Dr. Pramila Krishnamurthy, (King's College Hospital), as she discusses the latest updates in the diagnosis and management of (BPDCN). She will highlight the diagnosis of BPDCN and the treatment options available. Recent data from the ASH and EHA for tagraxofusp will be discussed with mentioning the adverse event management protocols. The audience will have an opportunity to ask questions at the end of the session.
Clinical challenges and therapeutic sequencing in relapsed refractory multiple myeloma
March 1, 2024, 02:20 p.m. To 02:45 p.m. Conrad Dubai.
Join our expert, Dr. Joshua Richter (Mount Sinai School of Medicine), as he discusses the current unmet needs in relapsed refractory multiple myeloma patients. He will highlight the data for treatment options available for second or later lines with educational part about the role of XPO1 inhibition in RRMM. Recent data from the ASH and EHA for Selinexor will be discussed with mentioning the adverse events prophylactic and management protocols. The audience will have an opportunity to ask questions at the end of the session.
Additional Information
If you would like further information, please contact:
Moustafa Abouhekal [email protected]
Pfizer
Addressing the Challenges in Sickle Cell Disease management: From Clinical trial to Clinical experience
March 1, 2024, 05:00 p.m. To 06:00 p.m.
An expert panel of Haematologists will share how they personally approach the treatment of SCD during an era of novel therapies. Each panelist will share a case study and discuss relevant data and treatment options. This will be an interactive session and challenge your clinical thinking.
Chairperson & Moderator:
Mahmoud Marashi - Professor of Medicine, Dubai Medical College Consultant Hematologist, Dubai Health Authority, UAE
Speakers:
Salam Alkindi - Professor & Consultant Hematologist College of Medicine & Health Sciences,
Sultan Qaboos University
Yasser Wali - Professor & Head of the Pediatric Hematology Unit Sultan Qaboos University
Jaffar Al Tooqi - SCD Team Leader at Bahrain MOH, 2014 till present.SCD management Board member since 2014. Training Coordinator for HBDC since 2016. Member of Bahrain MOH transfusion committee.
Novartis
TKIs sequencing and next generation of care and Unmet needs in CML and real-world experience
March 2, 2024, 5:30 p.m. – 6:00 p.m.
Drs. Rana and Osman will share TKIs sequencing practices and how they personally approach the treatment of CML during an era of novel therapies. Dr. Shabeeha Rana will address TKIs sequencing and next generation of care. Dr. Hani Osman will share interactive case studies from real-world experience.
Speakers:
Dr. Shabeeha Rana
Consultant Hematologist at Genesis Healthcare Center
With an impressive 16 years of clinical experience, Dr Shabeeha specialises in various haematological conditions, including malignant and laboratory haematology, focusing on conditions like Acute and chronic leukemia, Hodgkins and Non-Hodgkins lymphoma, multiple myeloma, and Amyloidosis. She is the pioneer of first hematopoietic stem cell transplantation program in Dubai and duly led the program as the Director of Clinical haematology, HSCT, and Cellular Therapy at the American Hospital Dubai.
Dr Shabeeha has had a distinguished career, marked by tenures at prestigious healthcare institutions like the Royal Marsden Hospital London, University Hospitals Birmingham and was appointed as Consultant Haematologist at the Kings College Hospital London, before moving to Dubai in 2018.
Dr Shabeeha graduated from The Aga Khan Medical University in Pakistan, earning her MBBS. She further honed her skills in the United Kingdom, acquiring a Certificate of Completion of Training (CCT) in Haematology and Haemato-Oncology. She is duly registered and licensed to practice on the GMC register.
Dr. Hani Osman
Consultant Hematologist/Oncologist at Tawam
Dr. Hani Yousif Osman graduated from the Faculty of the Medicine University of Khartoum Sudan. He moved to the United Kingdom where he completed his training in internal medicine and obtained his MRCP (UK) degree, Fellowship from the Royal college of pathologists and CCT. He completed his high specialist training in hematology at the University of Cardiff hospital UK. His research focuses on acute myeloid leukemia novel therapy, He has extensive hematology consultant experience in the UK, Saudia Arabia, and the United Arab Emirates. Dr. Osman was involved and the principal investigator for many clinical trials and he has over 30 publications.
Moderator:
Dr. Amar Lal:
Consultant Hematologist/Oncologist at Tawam
Dr. Amar Lal is an experienced Oncologist with a demonstrated history of working in the hospital & health care industry. He is skilled in Clinical Research, Medical Education, Oncology, Medicine, and Emergency Medicine. Strong healthcare services professional with an ESMO Certification focused on medical oncology certification from the European society of medical oncology.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission